Last reviewed · How we verify

NCT06432400: IRTIPAP

Identification of Post-Traumatic Stress Disorder in Adult Patients With Substance Use Disorders Followed up in the Medical and Psychological Centre: Multicentre Descriptive Study

Withdrawn NA Last updated 10 March 2025
What this trial tests

NA trial testing Patient questionnaires in Trauma. Withdrawn.

Timeline
1 December 2024
Primary endpoint
1 December 2025
1 December 2025

Quick facts

Lead sponsorHôpital NOVO
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Start date1 December 2024
Primary completion1 December 2025
Estimated completion1 December 2025
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Hôpital NOVO — full company profile →

Who can join

18 and older, any sex, with Trauma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The aim of this study is to show that early identification of PTSD and CPTSD would increase recognition of these disorders and facilitate diagnosis, referral and recovery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Patient questionnaires

Trials testing the same drug.

Other recruiting trials for Trauma

Currently open trials in the same condition.

Other Hôpital NOVO trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06432400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing